Noveris Health Sciences is trading 21.74% down at $0.09, with no clear company-specific catalyst identified for September 8, 2026.
- Recent disclosures included a six-month net loss of $1,593,691.
- A proposed C$500,000 convertible-debenture financing was also disclosed; available coverage does not directly link either development to today’s decline.
- The broader Canadian market backdrop is weaker, but insufficient to explain the full move.